photo of white medication pill on teal surface
Ohio Clinic Says It Won’t Administer Alzheimer’s Drug to Patients – The New York Times

The Cleveland Clinic, one of the largest and most respected medical centers in the U.S., has decided not to administer the new Alzheimer’s drug Aduhelm.

  • “The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A.”
  • photo by Dustin Franz for The New York Times
  • article by By Pam Belluck for The New York Times

  • Cleveland Clinic, Mount Sinai say they won’t administer Aduhelm. Aducanumab, branded as Aduhelm, was cleared by the FDA June 7 using the agency’s accelerated approval pathway, marking the first Alzheimer’s drug approved by the agency in two decades.

    • Translation to Spanish
    • Cleveland Clinic, Mount Sinai dice que no administrarán Aduhelm. Aducanumab, de marca Aduhelm, fue aprobado por la FDA el 7 de junio utilizando la vía de aprobación acelerada de la agencia, lo que marca el primer medicamento para el Alzheimer aprobado por la agencia en dos décadas.

    Cleveland Clinic photo by Dustin Franz for The New York Times